Skip to Main Content

Advertisement

Issue Archive

Table of Contents

INSIDE BLOOD COMMENTARIES

INSIDE BLOOD COMMENTARY
INSIDE BLOOD COMMENTARY
INSIDE BLOOD COMMENTARY
INSIDE BLOOD COMMENTARY
INSIDE BLOOD COMMENTARY

BLOOD WORK

PLENARY PAPER

PERSPECTIVES

BLOOD SPOTLIGHT

HOW I TREAT

CLINICAL TRIALS AND OBSERVATIONS

HEMATOPOIESIS AND STEM CELLS

IMMUNOBIOLOGY

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

PLATELETS AND THROMBOPOIESIS

TRANSPLANTATION

RETRACTIONS

  • Cover Image

    Cover Image

    issue cover

    AF6 is a cytoplasmic protein with two distinctive features: one single PDZ and two RAS-interacting (RA) domains. These characteristics enable AF6, either alone or when fused to MLL, to modulate multiple signal transduction pathways in vivo, especially those involving RAS. The authors demonstrate that MLL-AF6 affects AF6 localization in t(6;11) myeloid leukemia cells in order to aberrantly activate RAS (green) and its downstream signaling to empower the tumorigenic potential. The silencing of MLL-AF6 relocalizes the AF6 protein back into the cytoplasm, leading to reduction of both RAS levels and activity. These results imply that RAS may play a crucial oncogenic role in this subtype of AML. See the article by Manara et al on page 263.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkTable of Contents
  • PDF Icon PDF LinkBack Matter
  • PDF Icon PDF LinkAdvertising
  • PDF Icon PDF LinkEditorial Board
Close Modal
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close Modal
Close Modal

Advertisement

X